MMC Maxman XI tablets

Safety advisory

2 May 2017

MMC Maxman XI tablets pose a serious risk to your health and should not be taken.

The Therapeutic Goods Administration (TGA) has tested a product labelled MMC Maxman XI tablets and found that:

Packaging for MMC Maxman XI tablets

  • the tablets contain the undeclared substance sildenafil.

Consumers are advised that sildenafil is a prescription-only substance in Australia.

The supply of MMC Maxman XI tablets containing undisclosed sildenafil is illegal.

MMC Maxman XI tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation, and the place of manufacture is not approved by the TGA.

TGA investigations have shown that a number of people in Australia may have bought the product online.

Information for consumers

  • Stop taking MMC Maxman XI tablets and take any remaining tablets to your local pharmacy for safe disposal.
  • If you have any concerns arising from your use of this product, consult your health care practitioner.

Action the TGA is taking

The TGA is working with the Australian Border Force (ABF) to help stop future shipments MMC Maxman XI tablets from entering Australia.

If these tablets are found at the border by the ABF they will be seized and destroyed.

The TGA is advising consumers to exercise extreme caution when purchasing medicines from unknown overseas Internet sites and has produced a short video on the risks associated with buying medicines and medical devices online. Products purchased over the Internet

  • may contain undisclosed and potentially harmful ingredients
  • may not meet the same standards of quality, safety and efficacy as those approved by the TGA for supply in Australia.

Report counterfeit medicines and medical devices

If you are worried about counterfeit medicines or medical devices, and want to report an issue, you can report the matter to the TGA:

How to report
Phone: 1800 020 653
Online: Report a perceived breach of the Therapeutic Goods Act or questionable practices relating to therapeutic products
Email: